吉利德本月将公布中国研究结果，巴克莱警告称该股上涨空间不大

英为财情2020-04-08

英为财情Investing.com – 4月份，随着全球确诊病例逾140万人，华尔街的关注焦点放到吉利德科学公司 (NASDAQ:GILD)即将公布的试验性药物研究结果上。因潜在疫苗的研发需要逾一年时间，瑞德西韦是近期治疗新冠病毒的希望之一。吉利德预计会在本月公布在中国进行的晚期研究结果，并在5月份公布美国的试验结果。从1月下旬至3月初，吉利德科学的估值飙升超过200亿美元；但在3月6日触及...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

自由之路_0738
2020-04-09
自由之路_0738
一个想骗筹码的骗子
一度过了么
2020-04-08
一度过了么
中国一线防疫专家多次表示，在中国的临床使用中从整个疫情防治来看肯定是起到了很好的作用的，所以临床试验结果80%应该是有效的，这个某某是个对中国疫情控制成效有偏见的做空者，他就等着爆仓吧
咖啡因
2020-04-08
咖啡因
巴克莱是个什么鬼？

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2025420540?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","is_english":false,"pubTime":"2020-04-08 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2025420540","market":"us","top_or_hot":-1,"title":"吉利德本月将公布中国研究结果，巴克莱警告称该股上涨空间不大","media":"英为财情","content":"<div>\n<p>英为财情Investing.com – 4月份，随着全球确诊病例逾140万人，华尔街的关注焦点放到吉利德科学公司 (NASDAQ:GILD)即将公布的试验性药物研究结果上。\n因潜在疫苗的研发需要逾一年时间，瑞德西韦是近期治疗新冠病毒的希望之一。吉利德预计会在本月公布在中国进行的晚期研究结果，并在5月份公布美国的试验结果。\n\n从1月下旬至3月初，吉利德科学的估值飙升超过200亿美元；但在3月6日触及...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-1932108\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德本月将公布中国研究结果，巴克莱警告称该股上涨空间不大</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德本月将公布中国研究结果，巴克莱警告称该股上涨空间不大\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-04-08 15:24 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-1932108><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>英为财情Investing.com – 4月份，随着全球确诊病例逾140万人，华尔街的关注焦点放到吉利德科学公司 (NASDAQ:GILD)即将公布的试验性药物研究结果上。\n因潜在疫苗的研发需要逾一年时间，瑞德西韦是近期治疗新冠病毒的希望之一。吉利德预计会在本月公布在中国进行的晚期研究结果，并在5月份公布美国的试验结果。\n\n从1月下旬至3月初，吉利德科学的估值飙升超过200亿美元；但在3月6日触及...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-1932108\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-1932108","article_id":"2025420540","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2025420540","pubTimestamp":1586330655,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"英为财情Investing.com – 4月份，随着全球确诊病例逾140万人，华尔街的关注焦点放到吉利德科学公司 (NASDAQ:GILD)即将公布的试验性药物研究结果上。\n因潜在疫苗的研发需要逾一年","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Geely will release the results of China research this month, and Barclays warns that there is little room for the stock to rise.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"英为财情Investing.com – 4月份，随着全球确诊病例逾140万人，华尔街的关注焦点放到吉利德科学公司 (NASDAQ:GILD)即将公布的试验性药物研究结果上。\n因潜在疫苗的研发需要逾一年时间，瑞德西韦是近期治疗新冠病毒的希望之一。吉利德预计会在本月公布在中国进行的晚期研究结果，并在5月份公布美国的试验结果。\n\n从1月下旬至3月初，吉利德科学的估值飙升超过200亿美元；但在3月6日触及两年高点之后，该股一直横盘整理。巴克莱警告说，该股的上涨空间可能不大，给出“减持”评级。\n\n巴克莱估计吉利德在中国的两项研究只有20%的机会（一项针对轻至中度症状的患者，另一项针对重症患者）获得成功。即便取得成功，吉利德科学还需面临复杂的制造过程、定价和药品出售等困难。\n\n巴克莱认为，如果两项研究失败，吉利德的股价可能跌至危机发生前的60美元低位。\n\n吉利德科学公司 (NASDAQ:GILD)股价周二下跌3.94%，报74.67美元。\n\n【本文来自英为财情Investing.com，阅读更多请登录cn.Investing.com或英为财情 App】\n推荐阅读：\n FDA紧急授权部分氯喹类药物用于COVID-19治疗，诺华、拜耳等医药股或受益\n吉利德科学申请撤销瑞德西韦孤儿药资格，放弃附带权益\n新冠疫苗研发竞争加剧！这三只生物制药股谁会成为赢家？\n中概股信任危机\n（编辑：莫宁）","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":921786478,"gmtCreate":1586386114894,"gmtModify":1704361121798,"author":{"id":"3503596379936088","authorId":"3503596379936088","name":"自由之路_0738","avatar":"https://static.tigerbbs.com/75752e4fa04abb72cb146a59df86e393","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3503596379936088","authorIdStr":"3503596379936088"},"htmlText":"一个想骗筹码的骗子","listText":"一个想骗筹码的骗子","text":"一个想骗筹码的骗子","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/921786478","repostId":2025420540,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":921429156,"gmtCreate":1586356666175,"gmtModify":1704361016042,"author":{"id":"3435957463939049","authorId":"3435957463939049","name":"一度过了么","avatar":"https://static.tigerbbs.com/c71f2c80b9f5ac336b495eda7cb89b3a","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3435957463939049","authorIdStr":"3435957463939049"},"htmlText":"中国一线防疫专家多次表示，在中国的临床使用中从整个疫情防治来看肯定是起到了很好的作用的，所以临床试验结果80%应该是有效的，这个某某是个对中国疫情控制成效有偏见的做空者，他就等着爆仓吧","listText":"中国一线防疫专家多次表示，在中国的临床使用中从整个疫情防治来看肯定是起到了很好的作用的，所以临床试验结果80%应该是有效的，这个某某是个对中国疫情控制成效有偏见的做空者，他就等着爆仓吧","text":"中国一线防疫专家多次表示，在中国的临床使用中从整个疫情防治来看肯定是起到了很好的作用的，所以临床试验结果80%应该是有效的，这个某某是个对中国疫情控制成效有偏见的做空者，他就等着爆仓吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/921429156","repostId":2025420540,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":921438926,"gmtCreate":1586351752165,"gmtModify":1704360968355,"author":{"id":"3440729020227084","authorId":"3440729020227084","name":"咖啡因","avatar":"https://static.tigerbbs.com/4f0cb4b71b20ccc2729bafe944dab61c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3440729020227084","authorIdStr":"3440729020227084"},"htmlText":"巴克莱是个什么鬼？","listText":"巴克莱是个什么鬼？","text":"巴克莱是个什么鬼？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/921438926","repostId":2025420540,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2025420540"}